Guideline on Classification of Advanced Therapy Medicinal Products

Draft

<table>
<thead>
<tr>
<th>Date of publication</th>
<th>15 April 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of implementation</td>
<td>To be announced</td>
</tr>
</tbody>
</table>

This document is a draft SFDA guideline published for comments and suggestions purposes. It is, therefore, subject to alteration and modification and may not be referred to as SFDA guideline until approved by SFDA.
Guideline on Classification of Advanced Therapy Medicinal Products

Draft

Saudi Food & Drug Authority
Drug Sector

Please send your comments or suggestions before June 14, 2020 to: Drug.comments@sfda.gov.sa

Saudi Food and Drug Authority

Vision and Mission

**Vision**
To be a leading international science-based regulator to protect and promote public health

**Mission**
Protecting the community through regulations and effective controls to ensure the safety of food, drugs, medical devices, cosmetics, pesticides and feed
<table>
<thead>
<tr>
<th>Version</th>
<th>Author</th>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Draft</td>
<td>Executive Directorate of Products Evaluation</td>
<td>15 April 2020</td>
<td>-</td>
</tr>
</tbody>
</table>
## ACRONYMS AND ABBREVIATIONS

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATMP</td>
<td>Advanced Therapy Medicinal Product</td>
</tr>
<tr>
<td>CBMP</td>
<td>Cell Based Medicinal Product (includes both CTMP and TEP)</td>
</tr>
<tr>
<td>CTMP</td>
<td>Cell Therapy Medicinal Product (CBPM sub-group)</td>
</tr>
<tr>
<td>GTMP</td>
<td>Gene Therapy Medicinal Product</td>
</tr>
<tr>
<td>ATMP Guideline</td>
<td>SFDA Guideline on Classification of Advanced Therapy</td>
</tr>
<tr>
<td>Guideline</td>
<td>Medicinal Products</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>HATL</td>
<td>Hospital Advanced Therapy License</td>
</tr>
<tr>
<td>KSA</td>
<td>Kingdom of Saudi Arabia</td>
</tr>
<tr>
<td>SFDA</td>
<td>Saudi Food and Drug Authority</td>
</tr>
<tr>
<td>TEP</td>
<td>Tissue Engineered Product (CBMP sub-group)</td>
</tr>
<tr>
<td>US FDA</td>
<td>United States of America Food and Drug Administration</td>
</tr>
</tbody>
</table>
TABLE OF CONTENTS

Acronyms and Abbreviations.................................................................5

1. Introduction......................................................................................7

2. Definitions for ATMP classification...................................................8
   2.1. Legal basis of ATMP classification ..............................................8
   2.1.1. Gene Therapy Medicinal Product ...........................................8
   2.1.2. Cell Based Medicinal Product ...............................................8
   2.1.3. Combined Advanced Therapy Medicinal Products ....................9
   2.1.4. Hospital Advanced Therapy License .....................................10
   2.1.5. Additional legal clarifications for classification of ATMPs .........11

3. Principles applied to the classification of ATMPs ..............................11
   3.1. Definitions applied to the classification of ATMPs .......................11
   3.1.1. Definition of cell and viable cell for classification purposes ........12
   3.1.2. Claimed mode of action (MoA) ..............................................12
   3.1.3. Criteria for GTMP ................................................................12
       Figure 1. DECISION TREE FOR GTMP ....................................13
   3.1.4. Criteria for Cell Based Medicinal Products (CBMP) .................14
       Figure 2. DECISION TREE FOR CBMP (includes sub-groups sCTMP and TEP) .........................................................16
   3.1.5. Criteria for combined ATMPs ..............................................17
   3.2. Evolving and borderlines areas ..................................................17
   3.2.1. Advanced therapies versus transplants/transfusion ..................17
   3.2.2. Gene Therapy Medicinal Product Versus Cell Based Medicinal Product .........................................................18
   Annex I Non-Substantial (minimal) manipulation ..............................19
1. INTRODUCTION

This Guideline provides legal definitions for Advanced Therapy Medicinal Product (ATMP) in KSA. The aim of ATMP Guideline is to provide guidance on the ATMP definitions, as well as on the interpretation of key concepts of the definition of gene therapy medicinal products and cell based medicinal products, and combined advanced therapy medicinal products.

ATMP classification will be based on the evaluation of whether a given product fulfills one of the definitions of gene therapy medicinal product (GTMP) or cell based medicinal product (CBMP), and whether the product fulfills the definition of a combined ATMP or not. However, SFDA acknowledges that due to the complex nature of these therapeutic products, the limited data package at an early stage of product development and the rapid evolution of science and technology, questions of borderline may arise. These will be addressed by SFDA on case-by-case basis. SFDA provides a consultation service through the electronic product classification system ePCS https://pcs.sfda.gov.sa/Default.En.aspx.

Since clinical trials and Hospital Advanced Therapy License for ATMPs are under the responsibility of the SFDA, it is important to stress that the ATMP classification may help when submitting clinical trial or Hospital Advanced Therapy License dossier, as the applicant and SFDA will clarify and facilitate identification of the most relevant criteria and procedure to be applied. For instance, whether Hospital Advanced Therapy License for particular technology will be considered.

The ATMP classification is conducted on basis of information provided by a developer of a product based on genes or cells and the outcome of the classification is therefore specific to the product under development. The ATMP classification will help developers to clarify the applicable regulatory framework. The ATMP classification will be a useful tool for applicants to initiate a tailored dialogue on the product development with SFDA. Applicants are advised to submit classification requests via the electronic system. Once the candidate ATMP classification has been clarified and confirmed, the dialogue can continue with the use of other SFDA procedures. Moreover, the ATMP classification can be applied at any stage of the product development, even when non-clinical and clinical data are not available. It should be noted that classifications are always related to a defined product. It is thus not possible to classify scientific ‘concepts’ in the absence of a clear description of the product.
2. Definitions for ATMP classification

2.1. Legal basis of ATMP classification

According to Guideline on ATMP Classification, the term ‘advanced therapy medicinal product’ means any of the following medicinal products for human use:

- Gene therapy medicinal product

- Cell based medicinal product (includes both somatic cell therapy medicinal products and tissue engineered products)

- “Combined ATMP” products contain as an integral part of the product also a medical device.

2.1.1. Gene therapy medicinal product
Gene therapy medicinal product means a biological medicinal product which has the following characteristics:

- it contains an active substance which contains or consists of a recombinant nucleic acid used in or administered to human beings with a view to regulating, repairing, replacing, adding or deleting a genetic sequence;

- its therapeutic, prophylactic or diagnostic effect relates directly to the recombinant nucleic acid sequence it contains, or to the product of genetic expression of this sequence. Gene therapy medicinal products shall not include vaccines against infectious diseases.

In order to be considered a gene therapy medicinal product, both the characteristics (a) and (b) have to be fulfilled.

2.1.2. Cell based medicinal product

Cell based products includes cell based ATMPs - somatic cell therapy medicinal products (sCTMPs) and tissue engineered products (TEPs).

Somatic cell therapy medicinal product (sCTMPs) means a biological medicinal product which has the following characteristics:

- contains or consists of cells or tissues that have been subject to substantial manipulation so that biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered, or of cells or tissues that are not intended to be used for the same essential function(s) in the recipient and the donor;

- is presented as having properties for, or is used in or administered to human beings with a view to treating, preventing or diagnosing a disease through the pharmacological, immunological or metabolic action of its cells or tissues.
For the purposes of point (a), Annex I of ATMP Guideline provides detailed description of non-substantial manipulations. It should be noted that this list of non-substantial manipulations may evolve as state-of-the-art and knowledge advances.

It should also be noted that in order to be considered a somatic cell therapy medicinal product, both the characteristics have to be fulfilled.

Tissue engineered product (TEP) means a product that:

- contains or consists of engineered cells or tissues, and

- is presented as having properties for, or is used in or administered to human beings with a view to regenerating, repairing or replacing a human tissue.

A tissue engineered product may contain cells or tissues of human or animal origin, or both. The cells or tissues may be viable or non-viable. It may also contain additional substances, such as cellular products, bio-molecules, biomaterials, chemical substances, scaffolds or matrices.

Products containing or consisting exclusively of non-viable human or animal cells and/or tissues, which do not contain any viable cells or tissues and which do not act principally by pharmacological, immunological or metabolic action, are excluded from this definition.

Classification rule also states that:

Cells or tissues shall be considered ‘engineered’ if they fulfill at least one of the following conditions:

- the cells or tissues have been subject to substantial manipulation, so that biological characteristics, physiological functions or structural properties relevant for the intended regeneration, repair or replacement are achieved. The manipulations listed in Annex I, in particular, shall not be considered as substantial manipulations,

- the cells or tissues are not intended to be used for the same essential function or functions in the recipient as in the donor.

2.1.3. Combined Advanced Therapy Medicinal Products

Combined advanced therapy medicinal product means an advanced therapy medicinal product that fulfills the following conditions:

- it must incorporate, as an integral part of the product, one or more medical devices or one or more active implantable medical devices, and

- its cellular or tissue part must contain viable cells or tissues, or

- its cellular or tissue part containing non-viable cells or tissues must be liable to act upon the human body with action that can be considered as primary to that of the devices referred to.

For requirements for medical devices and implantable medical devices, please consult SFDA Medical
Device Department as appropriate. Medical Device marketing requirements are described in the MDS – G5 Guidance on Requirements for Medical Device Listing and Marketing Authorization. For more information on medical device classification, please refer to MDS – G42 Guidance on Medical Devices Classification.

2.1.4. Hospital Advanced Therapy License

ATMPs which are prepared in the territory of KSA according to specific quality standards set by SFDA, and are used within in a hospital under the exclusive professional responsibility of a medical practitioner in order to comply with an individual medical prescription for a custom-made product for an individual patient may apply for the status of Hospital Advanced Therapy License (HATL), which excludes requirement to obtain marketing authorization. Manufacturing and use of HATL products shall be authorized by SFDA on case-by-case basis. Applicant hospitals and companies shall ensure that national traceability and pharmacovigilance requirements referred are equivalent to those in respective ATMP class, gene therapy or cell based product respectively. Due to inherent and unavoidable starting material differences, a number of autologous cell therapy applications resemble medical technology rather than classical medicinal product development process.

*Hospital Advanced Therapy License* must fulfill the following conditions:

- *The ATMP must be prescribed by a medical practitioner*
- *The ATMP must be custom made to meet an individual prescription and preparation*
- *The ATMP must be used in a hospital*

Standards that are required under Hospital Advanced Therapy License:

1. **Good manufacturing practice and quality**

Requirements for manufacturing under HATL shall be authorized by SFDA. Manufacturer will be required to obtain HATL manufacturer’s license. The license will authorize the manufacture of particular categories of ATMPs (gene therapy or cell based therapy) rather than individual products in line with current manufacturer’s licensing arrangements. ATMPs made and used under HATL must comply with the principles of GMP. SFDA will inspect for compliance with GMP, which will be applied appropriately to the nature of the products involved. Inspections will be risk-based and in accordance with the concept of reducing administrative burdens – effective inspection and enforcement.

2. **Pharmacovigilance**

Manufacturers operating under HATL will be required to record any adverse reactions to an ATMP and notify SFDA of any suspected serious adverse reactions. At the point that a manufacturer’s license is sought to operate under HATL, SFDA will consider whether a risk management plan is necessary and may request one from the manufacturer. SFDA may also ask for a risk management plan from the manufacturer at any point. The risk management plan should provide details of the system in place to identify, characterize and minimize any risks related to the product. The clinician/medical practitioner using the ATMP under HATL
will be required to record all adverse reactions and report serious adverse reactions to SFDA.

3. Traceability
The traceability provisions that will apply include compliance with the requirements laid down SFDA as well as the traceability requirements under the SFDA Tissues and Cells legislation. Manufacturers of ATMPs under HATL must comply with those requirements. The hospital in which the ATMP is used will be required to establish and maintain a system for patient and product traceability containing sufficient detail to enable traceability between recipients of ATMPs and donors of the tissues and cells used in their manufacture. In the case of bankruptcy for ATMPs made and used under HATL, it would be a condition of operating under HATL scheme that arrangements are put in place by the manufacturer and hospital for the data to be transferred to SFDA in the event of a cessation of operations.

4. Reporting
Manufacturers operating under HATL will be required to make an annual report to SFDA. This report must set out the activities that are being carried out under HATL. This must include a description and number of batches and units manufactured in each of the categories of ATMPs for which a manufacturer’s license has been granted. Monitoring arrangements will enable SFDA to ensure the new scheme is working within the required parameters. Breaching the conditions applicable to the HATL will mean that an organization or individual could be liable to sanctions on the basis of placing a relevant medicinal product on the market without a marketing authorization. Sanctions and penalties that apply to other categories of medicines under the SFDA authorization procedure.

2.1.5. Additional legal clarifications for classification of ATMPs

With regards to products containing cells or tissues, it shall be noted that where a product contains viable cells or tissues, the pharmacological, immunological or metabolic action of those cells or tissues shall be considered as the principal mode of action of the product.

Demarcation rule between ATMP types states that a product which may fall within the definition of a somatic cell therapy medicinal product or a tissue engineered product, and a gene therapy medicinal product, shall be considered as a gene therapy medicinal product (i.e. CAR-T therapy).

3. Principles applied to the classification of ATMPs

3.1. Definitions applied to the classification of ATMPs

The following list of criteria is based on the state-of-the-art knowledge and analysis of ATMPs in other regions performed by SFDA. Nevertheless, these criteria should not be considered as exhaustive and might be subject to change as science and technology evolves.
3.1.1. Definition of cell and viable cell for classification purposes

For the purpose of ATMP classification, a cell is defined as follows: ‘A typical cell is the smallest unit of an organism that has been generated directly through mitosis. A cell comprises a nucleus (eukaryotic cells) or nucleoid material (prokaryotic cells) and cytoplasm enclosed by a cell membrane. A viable cell should be capable to produce energy and synthesize new molecules from raw materials.’

A viable cell is a cell that has a functional cytoplasmic membrane. In particular, the concerned method refers to cell staining by viability dyes and manual or automated analysis, under a light microscope or by flow cytometry, of a cell suspension in order to determine the percentage of viable cells.

3.1.2. Claimed mode of action (MoA)

Information on the claimed MoA is particularly important to ascertain whether the product is for treatment, prevention or diagnosis of a disease, and exerts its activity via a pharmacological, immunological or metabolic action, or whether the product is intended for regeneration, repair or replacement of cells/tissues. The possible MoA should be considered in relation to the intended indication. For example, if mesenchymal stem cells are used to treat a diseased organ, this could act via a combination of mechanisms which can include metabolic, immunological, pharmacological, regeneration and repair.

3.1.3. Criteria for GTMP

The definition of gene therapy medicinal product is articulated into two conditions that have both to be fulfilled simultaneously: 1) the product has to be a biological medicinal product and contains recombinant nucleic acid(s) and 2) the recombinant nucleic acid(s) should be directly involved in the mechanism of action (and hence therapeutic action of the product. In this respect the following observations can be made:

a) of the definition of Gene therapy medicinal product:
the recombinant nucleic acids should be of biological origin independently from the origin of the vector system used (e.g. viral/bacterial vectors or micellar and liposomal formulations, etc.)

(b) of the definition of Gene therapy medicinal product:
“its therapeutic, prophylactic or diagnostic effect relates directly to the recombinant nucleic acid sequence it contains, or to the product of genetic expression of this sequence”: the MoA and proposed indication, as claimed by the applicant are of essential to assess if there is a “direct” relationship between the therapeutic, prophylactic or diagnostic effect of the product and the delivered genetic sequence or the expressed product.
Figure 1. DECISION TREE FOR GTMP

- Biological active substance contains or consist a recombinant nucleic acid sequence

  - YES
  - Vaccine against infectious disease?

    - YES
    - Recombinant nucleic acid sequence used in or administered to human being with a view to regulating, repairing, replacing, adding or deleting a genetic sequence

      - NO
      - Not a GTMP

      - YES
      - Its primary therapeutic, prophylactic or diagnostic effect relates directly to the product of the expression of the recombinant nucleic acid sequence

        - NO
        - Not a GTMP

        - YES
        - GTMP

          - Does the product contain one or more medical device as an integral part of the product?

            - YES
            - Does the product contain (genetically modified) cells?

              - YES
              - Combined ATMP

              - NO
              - Not a combined ATMP

            - NO
            - GTMP

          - NO
          - Not a GTMP

- YES

- Not a GTMP
3.1.4. Criteria for cell based medicinal products (CBMP)

(I) Cell based medicinal products include both cell based product subgroups sCTMP and TEP - both contain or consist of engineered cells or tissues (see definition in ATMP Guideline section 2.1.2. above). To be considered ‘engineered’, cells or tissue(s) should fulfill at least one of the following criteria:

1. Substantial manipulation

Annex I of ATMP Guideline provides detailed description of non-substantial manipulations. The cells or tissue(s) have been manipulated during the manufacturing process so that their biological characteristics, physiological functions or structural properties have been modified to be relevant for their intended function. Examples of substantial manipulations include cell expansion (culture), genetic modification of cells, differentiation/activation with growth factors. Cell culturing leading to expansion is considered substantial manipulation. Induction of proliferation of cells during cell culture has to be regarded as changes of their biological characteristics and structural properties, either because of an immediate change in cell functionality or cell phenotype, or by increasing cell numbers to augment the desired function of the cells. Furthermore, most adherent cells, for example, are impacted by the repeated attachment and detachment cycles. It has been demonstrated that even the techniques applied for cell detachment might lead to different phenotypic changes especially on cell surface proteins (e.g. membrane receptors).

Enzymatic digestion of a tissue to release cells is also considered to be substantial manipulation, when the aim is to dissociate cell-cell contacts and the released cells are administered into patients with or without subsequent manipulation. An example would be keratinocytes from skin, for which enzymatic digestion would destroy the tissue architecture and functional interactions of the cells, which cannot be regained in the cell suspension: this would be considered as substantial manipulation.

If the enzymatic digestion leads to isolation of functionally intact tissue units (e.g. pancreatic islets and application for Edmonton Protocol) or there is scientific evidence that the original structural and functional characteristics are maintained, the procedure is not considered substantial manipulation.

In case a tissue is treated to remove cells and to be used without any cellular components (e.g. amniotic membrane, bone) the product is not an ATMP because it no longer contain cells or tissues.

If the number of certain cells (e.g. MSCs in fat grafts) is enriched by selection and the processing does not change the characteristics of the cells, this is not considered a substantial manipulation. Additionally, based on scientific considerations, SFDA can also consider other manipulations as “non substantial”. One example is the radiolabelling of leukocytes for diagnostic purposes. This technique has no significant impact on the functional properties of the cells and should thus not be considered a substantial manipulation.
2. Different essential function (non-homologous use)

Non-substantially manipulated cells or tissues used for the same essential function are not considered ATMPs. In case no substantial manipulation of the cells/tissues takes place, the classification is based on the essential function of the cells/tissues. The same essential function for a cell population means that the cells when removed from their original environment in the human body are used to maintain the original function(s) in the same anatomical or histological environment. Examples of this category are bone marrow cells or peripheral blood cells used for hematopoietic or immune reconstitution. Other clinical uses of bone marrow cells would be considered as ATMPs, unless the same essential function(s) and the same anatomical/histological environment can be demonstrated for the cells/tissues both at the donor and administration site (tissue). The same principle applies to other non-substantially manipulated cells from various origins, for example adipose cells transplanted to other than fat tissue are considered to be ATMPs.

Replacement of a tissue as its whole or functional unit of a tissue (such as cornea or pancreatic islets) is regarded as use for the same essential function. Similarly, transplantation of a non-manipulated tissue to another location in the same anatomical or histological environment is also considered to achieve the same essential function. This is the case for skin transplantation from one part of the body to another part, subcutaneous implantation of pancreatic islets or replacement of arteria by veins. However, in the case of pancreatic islets, the classification will also depend on the manipulation and functional integrity of the islets.

3. Inclusion and exclusions

- Products containing or consisting of animal cells or tissues to be administered to humans will always be considered as ATMPs.

- Products containing or consisting exclusively of non-viable cells or tissues and which do no act principally by pharmacological, immunological or metabolic action, will not be considered ATMPs.
Figure 2. DECISION TREE FOR CBMP (includes sub-groups sCTMP and TEP)

Explanatory notes:

*) see section 3.1.1 on what are considered viable cells. It should be noted that a product containing
exclusively non-viable cells/tissue and a medical device / active implantable medical device as an integral
part, will be considered a combined ATMP when these non-viable cells/tissues exert the primary action of
the combined product. This primary action should be based on the pharmacological, immunological or
metabolic action of the non-viable cells/tissues.
3.1.5. Criteria for combined ATMPs

Combined ATMPs incorporate an active substance, i.e. a cellular or tissue part consisting of viable or non-viable cells or tissues and of one or more medical devices or one or more active implantable medical devices as an integral part of the product. The medical device(s) should be used in the combination in the same way as its intended use without additional components. If cells or tissues are not viable, these must exert the primary action of the combined product.

It should be noted that normally the medical device should retain its intended purpose / mode of action in the combination to be considered as being “integral part” of the final product and thus qualify this product as a combined product. For those products where the function of the matrix is no longer considered to be linked to its structural properties, classification of non-combined ATMP will be applied by SFDA.

3.2. Evolving and borderlines areas

The ATMP classification procedure will also have to clarify borderline cases between ATMPs versus non-ATMPs as well as between the different product categories within the ATMP sphere. Below are given examples that illustrate the type of issues that are taken into consideration when assessing borderline cases.

3.2.1. Advanced therapies versus transplants/transfusion

Products consisting of cells or tissues may be at the border between SFDA Tissues and Cells legislation and the ATMP Guideline. Cells/tissues harvested and separated by a simple selection method (that does not result in a substantial manipulation of the cells/tissue) and re-administered to fulfill their same essential function will generally be regarded as non-ATMPs. However, depending on whether or not the selection process/method will alter the original characteristics of the cells/tissues may result in classification as ATMPs. Similarly, cells derived from human blood (e.g. lymphocytes) that are substantially manipulated or use for a different essential function are classified as ATMPs.

One example is that preparation of human pancreatic Langerhans’ islets (i.e. Edmonton Protocol) should not be classified as an ATMP. It will be considered that, for this preparation, the described process steps do not constitute substantial manipulations for the intended use so that there is no change in the biological characteristics of the islets. In addition, the product was intended to be used for the same essential function in the recipients, be it in the allogeneic or autologous conditions described. This conclusion is, however, not directly applicable to any other pancreatic beta cell products which may be submitted for classification, as they may be derived from very different and more complex process and substantial manipulations, i.e. cell-based product consisting of isolated beta-cells embedded in an alginate matrix.

In contrast, some products with an essentially minimal manipulation or maintenance of the initial biological properties can be classified as ATMP due to their intended use based on (a) different essential function(s) of the cells/tissues. For example, the use of autologous bone marrow-derived progenitor cells intended for treatment of patients with myocardial infarction or other vascular diseases would be considered as different
essential function and therefore such products are classified as ATMPs.

It is possible that cell-based products administered in the same anatomical location fall under the definition of ATMP on grounds that it is used for a different essential function. This can be encountered when the mode of action of the cells is not identical to the one attributed to the cells by the scientific knowledge, for example, the injection of concentrated bone marrow at the site of bone injury with the aim of healing a bone lesion.

3.2.2. Gene therapy medicinal product versus cell based medicinal product

Another borderline scenario can relate to products that are modified by adding an mRNA sequence, for example dendritic cells (DC) electroporated with mRNA in vitro and administrated to the patient to elicit a specific immune response. One could argue that the claimed mechanism of action is directly related to the expression of the mRNA encoded antigens to stimulate e.g. tumor specific immune responses. However, due to its relatively short half-life there may be little or no residual mRNA at the time of re-administration of the dendritic cells to the patient. Thus, it can be claimed that a recombinant nucleic acid is not administered to human beings with a view to adding a genetic sequence, but rather the mRNA electroporated DCs could be seen as an intermediate in the manufacturing process where the phenotype is finally altered without alteration of the genotype of the cells. Therefore, the product was considered not to comply with the definition of a gene therapy medicinal product. Instead, this ATMP Guideline considers that the product is a cell based therapy product as it consists of cells that were administered to human beings with a view to treating a disease through the immunological action of the modified cell populations.
Annex I  Non-Substantial (minimal) manipulation

This annex shall shed light on the term non-substantial or minimal manipulation when ATMP’s stakeholders/manufacturers wish to apply for a marketing authorization with SFDA. It should be noted that this list of non-substantial manipulations is non-exhaustive and may be updated by SFDA as science and technology evolves.

Non-Substantial Manipulation (Minimal manipulation) will be defined as:

1) For structural tissue, processing that does not alter the original relevant characteristics of the tissue relating to the tissue’s utility for reconstruction, repair, or replacement.

2) For cells or nonstructural tissues, processing that does not alter the relevant biological characteristics of cells or tissues.

Processing is defined as any activity performed on an ATMP, other than recovery, donor screening, donor testing, storage, labeling, packaging, or distribution, such as testing for microorganisms, preparation, sterilization, steps to inactivate or remove adventitious agents, preservation for storage, and removal from storage.

Processing can be either minimal or more than minimal manipulation depending on whether the processing alters the original relevant characteristics as detailed above.

Please note that all processing steps should be considered to determine whether the product is minimally manipulated.

Examples of non-substantial manipulation include:

- Cutting
- Grinding
- Enzymatic digestion
- Decellularization
- Resizing
- Fragmentation
- Shaping
- Centrifugation
For the purpose of this annex, please note that:

The main function of an ATMP in the donor, determines the level of manipulation.

Structural tissue is composed of structural components and cells, and those cells are part of the structural tissue for the purposes of determining which definition of minimal manipulation applies.

Cells or nonstructural tissues are generally those that serve predominantly metabolic or other biochemical roles in the body such as hematopoietic, immune, and endocrine functions.